Opinion|Videos|June 5, 2025
An Academic Perspective to Making First-Line Treatment Decisions for EGFR-mutated Metastatic NSCLC
Author(s)Rachel E. Sanborn, MD
An expert discusses treatment goals for patients with EGFR-mutated advanced/metastatic NSCLC, how to approach combination therapy with high-risk patients, and how recent data has influenced their practice.
Advertisement
Episodes in this series
- What are your treatment goals for patients with EGFR-mutated A/M NSCLC?
- How do you discuss combination therapy with your high-risk EGFR-mutated locally advanced/metastatic patients?
- How has your practice adapted given recent data?
Advertisement
Related to this article
Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.
Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
4
Sofetabart Mipitecan Elicits Responses Across FRα Levels in Ovarian Cancer
5